Europe - EPA:ALGEN - FR0004053510 - Common Stock
The current stock price of ALGEN.PA is 2.48 EUR. In the past month the price decreased by -15.93%. In the past year, price decreased by -28.32%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 69.32 | 45.88B | ||
| 1AE.DE | ARGENX SE | 67.91 | 44.95B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.86B | ||
| 2X1.DE | ABIVAX SA | N/A | 6.90B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.11B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.84B | ||
| 5CV.DE | CUREVAC NV | 5.17 | 1.01B | ||
| NANO.PA | NANOBIOTIX | N/A | 929.59M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 483.52M | ||
| FYB.DE | FORMYCON AG | N/A | 360.47M | ||
| VLA.PA | VALNEVA SE | N/A | 321.33M |
genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 143 full-time employees. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
GENOWAY SA
Technopark 2, 31 Rue Saint Jean-de-Dieu
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 128
Phone: 33437654100
genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 143 full-time employees. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
The current stock price of ALGEN.PA is 2.48 EUR. The price increased by 0.4% in the last trading session.
ALGEN.PA does not pay a dividend.
ALGEN.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
GENOWAY SA (ALGEN.PA) currently has 128 employees.
ChartMill assigns a fundamental rating of 6 / 10 to ALGEN.PA. ALGEN.PA scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months ALGEN.PA reported a non-GAAP Earnings per Share(EPS) of 0.21. The EPS increased by 18.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.86% | ||
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| Debt/Equity | 0.26 |
9 analysts have analysed ALGEN.PA and the average price target is 6.02 EUR. This implies a price increase of 142.66% is expected in the next year compared to the current price of 2.48.
For the next year, analysts expect an EPS growth of -100% and a revenue growth -7.14% for ALGEN.PA